AID  Vol.8 No.4 , December 2018
Colistin Use and Its Resistance in Kingdom of Saudi Arabia: A Narrative Review
Abstract: Antibiotic resistance is steadily increasing all over the world and has become a major public health challenge. To this end, colistin, an old bactericidal antibiotic of polymyxins family, has been recently re-introduced as only available last-resort antibiotic arsenal for treatment of infections caused by multidrug resistant (MDR)-Gram-negative bacteria. However, the continual and extensive use of colistin has led to the emergence and rapid spreading of its bacterial resistance and non-susceptibility that is currently experiencing a critical healthcare issue with extensive global concern. Both transferable and intrinsic mechanisms of bacterial resistance to colistin have been documented in several countries and, therefore, comprehensive epidemiological data and reports are urgently needed to better understand the current status of this important antibiotic to properly optimize its clinical significance. In consistency, the present narrative review highlights both clinical use and reported bacterial resistance of colistin in the Kingdom of Saudi Arabia.
Cite this paper: Faidah, H. (2018) Colistin Use and Its Resistance in Kingdom of Saudi Arabia: A Narrative Review. Advances in Infectious Diseases, 8, 255-261. doi: 10.4236/aid.2018.84021.

[1]   Storm, D.R., Rosenthal, K.S. and Swanson, P.E. (1977) Polymyxin and Related Peptide Antibiotics. Annual Review of Biochemistry, 46, 723-763.

[2]   Nakajima, S. (1965) Clinical Use of Colimycin Fotic Solution. Jibiinkoka Otolaryngology, 37, 693.

[3]   Ohzawa, R. (1965) The Use of Colimycin Eardrops. Jibiinkoka Otolaryngology, 37, 585.

[4]   Falagas, M.E., Kasiakou, S.K. and Saravolatz, L.D. (2005) Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clinical Infectious Diseases, 40, 1333-1341.

[5]   Cai, Y., Chai, D., Wang, R., Liang, B. and Bai, N. (2012) Colistin Resistance of Acinetobacter baumannii: Clinical Reports, Mechanisms and Antimicrobial Strategies. Journal of Antimicrobial Chemotherapy, 67, 1607-1615.

[6]   Jeannot, K., Bolard, A. and Plésiat, P. (2017) Resistance to Polymyxins in Gram-Negative Organisms. International Journal of Antimicrobial Agents, 49, 526-535.

[7]   Al-Tawfiq, J.A., Laxminarayan, R. and Mendelson, M. (2017) How Should We Respond to the Emergence of Plasmid-Mediated Colistin Resistance in Humans and Animals? International Journal of Infectious Diseases, 54, 77-84.

[8]   Li, J., Nation, R.L., Turnidge, J.D., et al. (2006) Colistin: The Re-Emerging Antibiotic for Multidrug Resistant Gram-Negative Bacterial Infection. Lancet, 9, 589-601.

[9]   Karvanen, M. (2013) Optimization of Colistin Dosage in the Treatment of Multiresistant Gram-Negative Infections (Dissertation). Uppsala Universiteit, Uppsala.

[10]   Leangapichart, T., Gautret, P., Brouqui, P., Mimish, Z., Raoult, D. and Rolain, J.-M. (2016) Acquisition of mcr-1 Plasmid-Mediated Colistin Resistance in Escherichia coli and Klebsiella pneumoniae during Hajj 2013 and 2014. Antimicrobial Agents and Chemotherapy, 60, 6998-6999.

[11]   Cara, A.K.S., Zaidi, S.T.R. and Suleman, F. (2018) Cost-Effectiveness Analysis of Low versus High Dose Colistin in the Treatment of Multi-Drug Resistant Pneumonia in Saudi Arabia. International Journal of Clinical Pharmacy, 40, 1051-1058.

[12]   Rana, M.A., Rahman, B.A., Mady, A.F., Odat, M.A., AlHarthy, A., Ramadan Oel, S., Mumtaz, S.A. and Omrani, A.S. (2014) Intra-Pleural Colistin Methanesulfonate Therapy for Pleural Infection Caused by Carbapenem-Resistant Acinetobacter Baumannii: A Successful Case Report. Infectious Disease Reports, 6, 5413.

[13]   Bukhary, Z., Mahmood, W., Al-Khani, A. and Al-Abdely, H.M. (2005) Treatment of Nosocomial Meningitis Due to a Multidrug Resistant Acinetobacter baumannii with Intraventricular Colistin. Saudi Medical Journal, 26, 656-658.

[14]   Al Shirawi, N., Memish, Z.A., Cherfan, A. and Al Shimemeri, A. (2006) Post-Neurosurgical Meningitis Due to Multidrug-Resistant Acinetobacter baumanii Treated with Intrathecal Colistin: Case Report and Review of the Literature. Journal of Chemotherapy, 18, 554-558.

[15]   Rico Caballero, V., Almarzoky Abuhussain, S., Kuti, J.L. and Nicolau, D.P. (2018) Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 62, pii: e02384-17.

[16]   Garbati, M.A., Abdulhak, A.B., Baba, K. and Sakkijha, H. (2013) Infection Due to Colistin-Resistant Enterobacteriaceae in Critically Ill Patients. Journal of Infection in Developing Countries, 7, 713-719.

[17]   Baadani, A.M., Thawadi, S.I., El-Khizzi, N.A. and Omrani, A.S. (2013) Prevalence of Colistin and Tigecycline Resistance in Acinetobacter baumannii Clinical Isolates from 2 Hospitals in Riyadh Region over a 2-Year Period. Saudi Medical Journal, 34, 248-253.

[18]   Uz Zaman, T., Albladi, M., Siddique, M.I., Aljohani, S.M. and Balkhy, H.H. (2018) Insertion Element Mediated mgrB Disruption and Presence of ISKpn28 in Colistin-Resistant Klebsiella pneumoniae Isolates from Saudi Arabia. Infection and Drug Resistance, 11, 1183-1187.

[19]   Abdallah, M. and Balshi, A. (2018) First Literature Review of Carbapenem-Resistant Providencia. New Microbes and New Infections, 25, 16-23.

[20]   Skov, R.L. and Monnet, D.L. (2016) Plasmid-Mediated Colistin Resistance (mcr-1 Gene): Three Months Later, the Story Unfolds. Eurosurveillance, 21, 30155.

[21]   Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., et al. (2016) Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. The Lancet Infectious Diseases, 16, 161-168.

[22]   Baron, S., Hadjadj, L., Rolain, J.M. and Olaitan, A.O. (2016) Molecular Mechanisms of Polymyxin Resistance: Knowns and Unknowns. International Journal of Antimicrobial Agents, 48, 583-591.

[23]   Rolain, J.M., Kempf, M., Leangapichart, T., et al. (2016) Plasmid-Mediated MCR-1 Gene in Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae in France and Laos. Antimicrobial Agents and Chemotherapy, 60, 6994-6995.

[24]   Lippa, A.M. and Goulian, M. (2009) Feedback Inhibition in the PhoQ/PhoP Signaling System by a Membrane Peptide. PLOS Genetics, 5, e1000788.

[25]   Wertheim, H., Van Nguyen, K., Hara, G.L., Gelband, H., Laxminarayan, R., Mouton, J., et al. (2013) Global Survey of Polymyxin Use: A Call for International Guidelines. Journal of Global Antimicrobial Resistance, 1, 131-134.

[26]   Nation, R.L., Li, J., Cars, O., Couet, W., Dudley, M.N., Kaye, K.S., et al. (2015) Framework for Optimisation of the Clinical Use of Colistin and Polymyxin B: The Prato Polymyxin Consensus. The Lancet Infectious Diseases, 15, 225-234.

[27]   Spapen, H., Jacobs, R., Van Gorp, V., Troubleyn, J. and Honoré, P.M. (2011) Renal and Neurological Side Effects of Colistin in Critically Ill Patients. Annals of Intensive Care, 1, 14.

[28]   Loho, T. and Dharmayanti, A. (2015) Colistin: An Antibiotic and Its Role in Multiresistant Gram-Negative Infections. Acta Medica Indonesiana, 47, 157-168.

[29]   Cascio, A., Conti, A., Sinardi, L., Iaria, C., Angileri, F.F. and Stassi, G. (2010) Post-Neurosurgical Multidrug-Resistant Acinetobacter baumannii Meningitis Successfully Treated with Intrathecal Colistin. A New Case and a Systematic Review of the Literature. International Journal of Infectious Diseases, 14, e572-e579.

[30]   Markou, N., Markantonis, S.L., Dimitrakis, E., Panidis, D., Boutzouka, E., Karatzas, S., et al. (2008) Colistin Serum Concentrations after Intravenous Administration in Critically Ill Patients with Serious Multidrug-Resistant, Gram-Negative Bacilli Infections: A Prospective, Open-Label, Uncontrolled Study. Clinical Therapeutics, 30, 143-151.

[31]   Shibl, A., Al-Agamy, M., Memish, Z., Senok, A., Khader, S.A. and Assiri, A. (2013) The Emergence of OXA-48- and NDM-1-Positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. International Journal of Infectious Diseases, 17, e1130-e1133.

[32]   Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. (2009) Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 53, 3430-3436.

[33]   Mohamed, A.F., Karaiskos, I., Plachouras, D., Karvanen, M., Pontikis, K., Jansson, B., et al. (2012) Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. Antimicrobial Agents and Chemotherapy, 56, 4241-4249.

[34]   Omrani, A.S., Alfahad, W.A., Shoukri, M.M., Baadani, A.M., Aldalbahi, S., Almitwazi, A.A., et al. (2015) High Dose Intravenous Colistin Methanesulfonate Therapy Is Associated with High Rates of Nephrotoxicity: A Prospective Cohort Study from Saudi Arabia. Annals of Clinical Microbiology and Antimicrobials, 14, 3.